Amgen And Array Enter Development Agreement By: MarketMinute.com Stock News December 15, 2009 at 16:05 PM EST Amgen Inc. (Nasdaq: AMGN) and Array BioPharma Inc. (Nasdaq: ARRY) will jointly develop a type 2 diabetes treatment. Shares of Array leaped 53 cents to close at $2.78 while Amgen stock fell $1.11 to close at $55.75. Related Stocks: Amgen Array Technologies Inc